FELIX study results reveal obe-cel’s potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.
New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia
- Post author:
- Post published:December 2, 2024
- Post category:uncategorized